Evaluation of anti-tumor efficacy of injectable Centchroman in mice bearing Ehrlich ascites carcinoma

Shenoy, B.D.; Udupa, N.; Kamath, R.; Devi, P.U.

Indian Journal of Physiology and Pharmacology 43(2): 259-262

1999


ISSN/ISBN: 0019-5499
PMID: 10365323
Document Number: 501586
Anti-tumor efficacy of Centchroman formulated as niosomes and gel implant was evaluated in Swiss albino mice bearing Ehrlich ascites carcinoma at 10 mg/kg body weight dose given subcutaneously. Median day of death, percentage increase in host life span and changes in body weight were studied. Centchroman significantly (P < 0.05) increased the median day of death both in free and formulated systems. Also, injectable formulations exhibited a significant (P < 0.05) increase in host life span compared to free drug, hence, enhanced anti-tumor efficacy against Ehrlich ascites carcinoma.

Document emailed within 1 workday
Secure & encrypted payments